Nantahala Capital Management LLC Makes New $2.34 Million Investment in Aytu BioPharma Inc. $AYTU

Nantahala Capital Management LLC acquired a new position in shares of Aytu BioPharma Inc. (NASDAQ:AYTU) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,086,812 shares of the company’s stock, valued at approximately $2,336,646. Nantahala Capital Management LLC owned 10.13% of Aytu BioPharma as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in AYTU. BlackRock Inc. purchased a new stake in shares of Aytu BioPharma during the second quarter worth about $49,000. Rothschild Wealth LLC acquired a new position in shares of Aytu BioPharma during the 4th quarter worth about $52,000. Dimensional Fund Advisors LP acquired a new position in shares of Aytu BioPharma during the 3rd quarter worth about $58,000. XTX Topco Ltd purchased a new position in Aytu BioPharma in the 4th quarter valued at about $67,000. Finally, DRW Securities LLC purchased a new position in Aytu BioPharma in the 4th quarter valued at about $76,000. 33.49% of the stock is owned by hedge funds and other institutional investors.

Aytu BioPharma Price Performance

Shares of NASDAQ AYTU opened at $2.25 on Friday. The firm has a 50-day simple moving average of $2.23 and a 200-day simple moving average of $2.35. The stock has a market capitalization of $24.14 million, a price-to-earnings ratio of -0.49 and a beta of 0.25. The company has a quick ratio of 1.00, a current ratio of 1.12 and a debt-to-equity ratio of 0.27. Aytu BioPharma Inc. has a 52 week low of $1.65 and a 52 week high of $3.07.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on AYTU shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aytu BioPharma in a research note on Monday, July 6th. Ascendiant Capital Markets raised their target price on Aytu BioPharma from $14.00 to $14.50 and gave the company a “buy” rating in a research report on Thursday, June 11th. Finally, Zacks Research raised Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 13th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $10.75.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.